Saturday, 31 October 2026European Markets

FORSEE POWER Stock Is 9% Up So Far On Thursday

Loading stream...

(vianews) - shares of forsee power (cac 40: forse.pa) rose 9.5% to €3.29 at 11:52 est on thursday, after five sequential sessions in a row of losses. cac 40 is jumping 0.4% to €7,496.44, after three sequential sessions in a row of losses. this seems, so far, a somewhat up trend exchanging session today.

about forsee power

forsee power société anonyme, together with its subsidiaries, engages in the design, manufacture, assemble, and supply of lithium-based battery systems for mobility applications in france, rest of europe, asia, the united states, and internationally. it operates in two segments: heavy vehicles, and light vehicles and industrial tech. the company's products are used in the field of autonomy and mobility for applications in bicycles, scooters, rolling stock, medical facilities, home automation, professional tools, etc.; electric transport for applications in buses, trucks, trams, shipping and rail transport, and marine and offshore vessels; and storage of electrical energy for residential, commercial, and industrial market applications. forsee power sas was incorporated in 2007 and is headquartered in ivry-sur-seine, france.

earnings per share

as for profitability, forsee power has a trailing twelve months eps of €-0.56.

volume

today's last reported volume for forsee power is 26806 which is 15.17% above its average volume of 23274.

more news about forsee power (forse.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com